Assessment of eosinophilic nasal inflammation in patients with severe asthma and nasal polyposis before and after six months of therapy with Benralizumab

J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6):2353-2357. doi: 10.23812/20-323-L.
No abstract available

Keywords: Benralizumab; eosinophils; nasal citology; nasal polyposis; severe asthma.

Publication types

  • Letter

MeSH terms

  • Anti-Asthmatic Agents* / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma* / drug therapy
  • Eosinophilia*
  • Eosinophils
  • Humans
  • Inflammation

Substances

  • Anti-Asthmatic Agents
  • Antibodies, Monoclonal, Humanized
  • benralizumab